Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.

A weight-loss drug more effective than Ozempic and Wegovy has recently been approved. Here’s how it works and how it compares ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

New weight-loss jabs for unemployed people to help them return to work could overwhelm “already stretched” NHS services, its ...

All the evidence gathered from the five-year trial will be used to demonstrate the long-term effect of weight loss medication ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and ...